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Introduction: Recognizing adverse drug reactions (ADRs) is becoming more important in clinical practice.
Objective: To determine the frequency of adverse drug reactions and ADR suspicions among 
the population affiliated to the Colombian health system and to describe the drugs, reactions and 
associated variables.
Materials and methods: We revised ADRs and ADRs suspicion databases from drugs dispensed 
by Audifarma, S.A., both for inpatient and outpatient care from 2007 to 2013. Variables included ADR 
report date, city, drug, drug’s Anatomical Therapeutic Classification (ATC), ADR severity, ADR type, 
ADR classification and ADR probability according to the World Health Organization’s definitions.
Results: We obtained 5,342 reports for 468 different drugs. The ATC groups with the most reports were 
anti-infectives for systemic use (25.5%), nervous system agents (17.1%) and cardiovascular system 
drugs (15.0%). The drugs with the highest number of reports were metamizole (4.2%), enalapril (3.8%), 
clarithromycin (2.8%), warfarin (2.5%) and ciprofloxacin (2.4%). The most common ADR, classified 
following the World Health Organization adverse reaction terminology, were: skin and appendages 
disorders (35.3%), general disorders (14.2%) and gastrointestinal system disorders (11.8%). Overall, 
49.4% of the ADRs were classified as “moderate” and 45.1% as “mild”.
Conclusion: An increasing number of ADR reports were found coinciding with a worldwide tendency. 
Differences between inpatient and outpatient ADR reports were found when compared to scientific 
publications. The information on ADR reports, mainly gathered by the Instituto Nacional de Vigilancia 
de Medicamentos y Alimentos – Invima, should be made public for academic and institutional use.
Key words: Drug-related side effects and adverse reactions, adverse drug reaction reporting systems, 
pharmacovigilance, Colombia. 
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Reacciones adversas a medicamentos en una población colombiana, 2007-2013: análisis de 
bases de datos
Introducción. La detección de las reacciones adversas a medicamentos es cada vez más importante 
en la práctica clínica.
Objetivo. Determinar la frecuencia de reacciones adversas a medicamentos y de los casos 
sospechosos de tales reacciones, en la población afiliada al Sistema General de Seguridad Social 
en Salud de Colombia. 
Materiales y métodos. Se revisaron las bases de datos sistematizadas de reportes de sospecha 
de reacciones adversas a los medicamentos dispensados por la empresa Audifarma, S.A., para uso 
ambulatorio y hospitalario, entre 2007 y 2013. Las variables contempladas fueron: la fecha de radicación 
del reporte, la ciudad, el medicamento, la clasificación anatómica terapéutica del medicamento, la 
gravedad, el tipo de reacción adversa y su clasificación, así como la de su probabilidad de ocurrir, 
según las definiciones de la Organización Mundial de la Salud (OMS).
Resultados. Se obtuvieron 5.342 reportes de sospecha de reacción adversa a 468 medicamentos 
diferentes. Los grupos con más reportes fueron los fármacos antiinfecciosos de uso sistémico                      
(25,5 %) y los medicamentos para el sistema nervioso (17,1 %) y para el sistema cardiovascular              
(15,0 %). Los medicamentos con más reportes fueron: el metamizol (dipirona) (4,2 %), el enalapril              
(3,8 %), la claritromicina (2,8 %), la warfarina (2,5 %) y la ciprofloxacina (2,4 %). Las reacciones 
adversas a medicamentos más frecuentes, según la clasificación de la terminología sobre reacciones 
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adversas de la OMS, fueron los trastornos de la piel y anexos (35,3 %), los trastornos generales           
(14,2 %) y los trastornos del sistema gastrointestinal (11,8 %). El 49,4 % de las reacciones adversas a 
medicamentos se catalogaron como moderadas y, el 45,1 %, como leves.
Conclusiones. Se encontró un incremento de reportes de reacciones adversas a medicamentos en los 
últimos años, lo que concuerda con la tendencia mundial. Se evidenciaron diferencias entre los reportes 
hospitalarios y de consulta ambulatoria. La información sobre los reportes de reacciones adversas a 
medicamentos, sobre todo la recopilada por el Instituto Nacional de Vigilancia de Medicamentos y 
Alimentos (Invima), debería ser pública para su uso académico e institucional.
Palabras clave: efectos colaterales y reacciones adversas relacionados con medicamentos, sistemas 
de registro de reacción adversa a medicamentos, farmacovigilancia, Colombia.
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Adverse drug reactions (ADR) are events that may 
severely affect the health of people who consume 
drugs for therapeutic, diagnostic or prophylactic 
purposes (1). ADRs have been shown to be an 
important worldwide cause of hospitalization and 
death every year and are among the top ten 
causes of death in the United States (2-5). Besides 
compromising people’s health, ADRs generate 
unexpected costs that affect the economy of health 
systems, which is why the early identification, 
prevention and resolution of ADRs are necessary 
(5-7). Several authors have calculated the per-
centage of preventable ADRs, demonstrating that a 
structured pharmacovigilance system could reduce 
human and economic repercussions generated 
by them (8,9).
In 2007, the World Health Organization (WHO) 
stated the importance of pharmacovigilance by 
releasing a resolution after the 27th Pan American 
Sanitary Conference urging member states to 
give priority to patient security by establishing and 
strengthening the scientific systems needed to 
improve security and attention quality (10).
The debate of active (search) and passive 
(spontaneous report) monitoring is open, contem-
plating costs and countries capacity in accordance 
with their own developmental level, with multiple 
considerations about experiences in different 
nations and the analysis of several classification 
and reporting systems (11-13).
Locally, the Instituto Nacional de Vigilancia de 
Medicamentos y Alimentos – Invima, the drug 
regulator entity in Colombia, constituted its national 
pharmacovigilance program in 1997, obtaining 
membership to the World Pharmacovigilance 
Program in 2004 with the recognition of a national 
initiative by the Uppsala Monitoring Center. Since 
then, ADR reports have been sent to the WHO 
collaborating center with regular feedback by 
the way of experts focused on standardizing the 
program. Trimestral bulletins with information 
on ADR reports, pharmacovigilance research 
and related news are published on its website 
(9,14). In 2006, the Colombian Health Minister 
established the Obligatory System of Health 
Attention Quality Guarantee by means of Decree 
No. 1011, making health institutions carry out 
an audit for the improvement of health attention 
quality by preventive actions and following-up drug 
dispensation and administration (15). This shows 
the importance of this topic in accordance to what 
has been discussed and adopted worldwide.
In 2011, a review of the literature published on 
research related to ADR detection in Colombian 
patients found 13 papers, including inpatient 
and outpatient populations monitored both pas-
sively and actively in institutions with different 
complexity levels. Nonetheless, these were small-
scale studies with non-unified information (14). A 
survey carried out in 2002 among pharmacology 
teachers in the country showed that there was 
no pharmacoepidemiology or pharmacovigilance 
teaching culture in Colombia (16).
We aimed at determining the frequency of ADRs 
and ADR suspicion in the Colombian health 
system (SGSSS) population by means of the 
ADR notification system owned by Audifarma, 
S.A. (main drug dispenser in Colombia) from 
January 2007 to March 2013, and at describing 
associated variables.
Materials and methods
A retrospective cross-sectional study was conducted, 
revising ADRs and ADR suspicion report databases 
of the drugs dispensed by Audifarma, S.A., both for 
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inpatient and outpatient populations, from January 
1st, 2007 to March 1st, 2013, when it began to be 
systematized information. Audifarma, S.A., is a 
drug dispensation logistic operator covering over 
6.2 million users of the SGSSS, corresponding to 
32.6% of the population affiliated to the pay system. 
The databases were completed by pharmaceu-
tical chemists associated with the company 
who received the report of Negative Outcomes 
Associated with Medication (NOM) including ADR 
suspicions, and data were verified with the help of 
a pharmacoepidemiologist if necessary. Databases 
presented variations on yearly information, so 
pertinent variables were manually standardized 
to create specific compilations by periods and a 
general compilation from 2007 to 2013 with all cases 
included. As this is a database used by several 
professionals across the country, information was 
carefully checked and terms were standardized.
The general database included: ADR report date, 
city, drug’s generic name, drug’s Anatomical 
Therapeutic Classification System (ATC) (code 
letter and first two digits), ADR severity (mild, 
moderate, serious), ADR type according to Edwards 
and Aronson (A, B, C, D, E, F) and ADR causality 
category according to WHO-UMC (Certain, Likely, 
Possible, Unlikely, Conditional, Unassessable). 
ADRs were standardized in accordance with WHO 
Adverse Drug Reaction Terminology (WHO-ART). 
The 15 drugs with the highest number of reports 
were classified and a list was created with the ADRs 
reported for them. The first 15 ATC subgroups (code 
letter and first two digits) were also extracted.
The study data were stored, processed, and 
analyzed using IBM SPSS®, Statistics, version 
21.0 (SPSS Inc., an IBM company, Chicago, 
Illinois, United States); frequencies, percentages 
and means were employed. The study protocol 
was reviewed and approved by the bioethics 
committee of the Universidad Tecnológica de 
Pereira, Colombia.
Results
The 5,342 ADRs and ADR suspicion reports were 
obtained from 55 cities, including 21 of the 32 
departments in the country. The ten municipalities 
with the most reports (Bogotá, Barranquilla, 
Cali, Pereira, Medellín, Barrancabermeja, Bello, 
Manizales, Ibagué and Cartagena) accounted for 
85.0% of the total. The number of reports per year 
was: 2007: 198 reports, 2008: 205 reports, 2009: 
383 reports, 2010: 661 reports, 2011: 1,397 reports, 
2012: 2,099 reports, and January-February 2013: 
399 reports. The mean number of monthly reports 
was 71. Altogether, 468 different drugs received at 
least one notification; table 1 shows the ATC group 
distribution for these.
ATC groups with the highest report numbers 
were: Anti-infectives for systemic use (J) (n=1360, 
25.5%), nervous system agents (N) (n=916, 
17.1%), cardiovascular drugs (C) (n=802, 15.0%), 
alimentary tract and metabolism drugs (A) (n=592, 
11.1%), and antineoplastic and immunomodulating 
agents (L) (n=530, 9.9%) (figure 1). Table 2 shows 
the top 15 ATC subgroups (code letter and first 
two digits).
The ATC group with the highest number of reports 
was “Anti-infectives for systemic use” with 17.7 
reports for each of the group’s drugs included in 
the database, while “Dermatologicals” obtained the 
lowest proportion, with 2.3 reports per drug.
The drugs with the highest number of reports were 
metamizole (4.2%), enalapril (3.8%), clarithromycin 
(2.8%), warfarin (2.5%) and ciprofloxacin (2.4%). 
In the list of the 15 drugs with the highest 
number of reports, there were four antibiotics 
(clarithromycin, ampicillin/sulbactam, ciprofloxacin 
and vancomycin), three antihypertensive drugs 
(losartan, nifedipine and enalapril), three analgesics/
antipyretics (metamizole, diclofenac and tramadol), 
two monoclonal antibodies (infliximab and 
rituximab), one anticoagulant (warfarin), one antie-
metic (metoclopramide) and one anti-ulcer drug 
(ranitidine) (table 3).
Table 1. Groups of drugs involved in adverse drug reactions 
among Colombian patients according to the Anatomical and 
Therapeutic Classification (ATC), 2007-2013
ATC group Frequency %
Nervous system (N)
Anti-infectives for systemic use (J)
Alimentary tract and metabolism (A)
Antineoplastic and immunomodulating 
agents (L)
Cardiovascular system (C)
Blood and blood forming organs (B)
Musculoskeletal system (M)
Respiratory system (R)
Genitourinary system and 
sex hormones (G)
Systemic hormonal preparations (H)
Dermatologicals (D)
Antiparasitic products, insecticides 
and repellents (P)
Sensory organs (S)
Various (V)
Total
77
73
59
56
54
24
23
23
22
18
14
13
8
4
468
16.5
15.6
12.6
12.0
11.5
5.1
4.9
4.9
4.7
3.8
3.0
2.8
1.7
0.9
100.0
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The most common ADRs, classified following the 
World Health Organization Adverse Reaction Ter-
minology (WHO-ART), were: Skin and appendages 
disorders, general disorders and gastrointestinal 
system disorders (table 4).
Table 5 specifically shows the most commonly 
reported ADRs for the 15 drugs with the highest 
number of reports.
For 3,292 reports (61.6% of the total), the severity of 
the notified ADR was indicated. Most were classified 
as “moderate” (n=1,626, 49.4%), followed by “mild” 
(n=1486, 45.1%), while “severe” ADRs were less 
common (n=176, 5.3%), even though there were 
3 (0.1%) lethal reactions. Data for ADR type were 
obtained for 3,233 (60.5%) of the reports, which 
showed that type B (dose-independent) were the 
most frequent (n=2,366, 73.2%), and just 782 
(24.2%) were type A (dose-dependent). There were 
also some notifications for type C (chronic) ADRs 
(n=64, 2.0%), type F (failure of therapy) (n=9, 0.3%) 
and type D or delayed (n=6, 0.2%).
Finally, 1,799 ADRs were classified as possible 
(45.0%), followed by likely (n=1,479, 37.0%), 
conditional (n=181, 4.5%), unlikely (n=170, 4.3%) 
and definitive (n=166, 4.2%). A total of 198 ADRs 
(5.0%) were unassessable.
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Figure 1. Total reports of adverse drug reactions in Colombia according to the Anatomical and Therapeutic Classification (ATC), 
2007-2013. A) Alimentary tract and metabolism, (B) blood and blood forming organs, (C) cardiovascular system, (D) dermatologicals, 
(G) genito-urinary system and sex hormones, (H) systemic hormonal preparations, (J) anti-infectives for systemic use, (L) antineoplastic and 
immunomodulating agents (M), musculoskeletal system, (N) nervous system, (P) antiparasitic products, insecticides and repellents, 
(R) respiratory system, (S) sensory organs, (V) various. 
Table 2. Reporting of adverse drug reactions attributed to the top 15 drug subgroups among Colombian patients according to the 
Anatomical and Therapeutic Classification (ATC), 2007-2013
ATC Sub-group description Reports Percentage
J01C
L04A
J01D
N02B
J01F
C09A
B01A
N02A
J01X
N03A
M01A
C10A
J01M
A02B
L01X
Beta-lactam antibacterials, penicillins
Immunosuppressants
Other beta-lactam antibacterials
Other analgesics and antipyretics
Macrolides, lincosamides and streptogramins
Agents acting on the renin-angiotensin system
Antithrombotic agents
Opioids
Other antibacterials
Antiepileptics
Antiinflammatory and antirheumatic products, non-steroids
Lipid modifying agents, plain
Quinolone antibacterials
Drugs for peptic ulcer and gastroesophageal reflux disease
Other antineoplastic agents
330
306
300
292
237
230
208
178
164
164
157
139
137
127
115
6.2
5.7
5.6
5.5
4.4
4.3
3.9
3.3
3.1
3.1
2.9
2.6
2.6
2.4
2.2
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Discussion
An increasing number of yearly ADR reports were 
found, a fact that coincides with a worldwide ten-
dency; differences between inpatient and outpatient 
ADR reports were evident when compared to 
scientific publications (17,18). No similar scientific 
papers had been published in the region which is a 
strength of this work.
Other studies in Colombia have used active 
pharmacovigilance in hospitalized patients and 
retrospective enquiries of medical attention due to 
ADRs, but this work included both in- and outpatient 
reports, and compared the frequency of adverse 
drug reactions in hospitals and ambulatory settings 
(14). A study in a hospital in Colombia found the 
same three ATC groups as those found with the 
highest number of reports in this case, but in the 
opposite order, probably as a result of only taking 
hospital ADR reports into account (19). Antibiotics, 
which are usually associated with ADRs, were 
the most common, but adverse reactions to 
insulin and heparin, which are common in other 
pharmacovigilance reports, were not frequently 
reported in this study (1,19,20). Biotechnologic 
drugs, such as infliximab and rituximab, also 
presented an important number of ADR reports. 
A press communiqué by Invima in 2013 reported 
the risk of serious dermatological ADRs and 
anaphylaxis due to rituximab and recommended 
the notification of any type of adverse reaction 
associated with this drug to the Institute (21).
Scientific literature usually exposes antibiotics as 
the drugs that are most commonly associated with 
ADR reports and, in this case, four of the top ten 
drugs with the highest number of reports were of 
that class, with ATC group J (anti-infectives for sys-
temic use) being first in the ADR report list (19,20).
Table 3. List of the 15 drugs with the highest number of adverse drug reactions in hospitals and ambulatory reports among Colombian 
patients, 2007-2013
ATC Drug Number of 
reports
Incidence 
x 1,000,000 
inhabitants/year
Number of 
hospital reports
n (%)
Number of 
ambulatory reports
 n (%)
N02BB02
C09AA02
J01FA09
B01AA03
J01MA02
N02AX02
J01CR01
C09CA01
L04AB02
J01XA01
A03FA01
C08CA01
A02BA02
M01AB05
L01XC02
Metamizole
Enalapril 
Clarithromycin
Warfarin
Ciprofloxacin
Tramadol
Ampicillin/sulbactam
Losartan
Infliximab
Vancomycin
Metoclopramide
Amlodipine
Ranitidine
Diclofenac
Rituximab
225
203
147
150
130
104
101
124
95
91
88
78
77
72
72
0.73
0.65
0.47
0.42
0.42
0.34
0.33
0.32
0.31
0.29
0.28
0.25
0.25
0.23
0.23
175 (7.6)
40 (1.7)
113 (4.9)
81 (3.5)
81 (3.5)
65 (2.8)
86 (3.8)
17 (0.7)
13 (0.6)
72 (3.1)
52 (2.3)
7 (0.3)
60 (2.6)
44 (1.9)
11 (0.5)
50 (1.5)
163 (4.9)
34 (1.1)
69 (2.1)
49 (1.5)
39 (1.2)
15 (0.4)
107 (3.3)
82 (2.5)
19 (0.5)
36 (1.0)
71 (2.2)
17 (0.5)
28 (0.8)
61 (1.9)
Table 4. The most common adverse drug reactions classified 
according to the World Health Organization Adverse Reaction 
Terminology (WHO-ART), Colombia, 2007-2013
System-organ class Frequency %
Skin and appendages disorders
Body as a whole - general disorders
Gastrointestinal system disorders
Central & peripheral nervous 
system disorders
Application site disorders
Respiratory system disorders
Cardiovascular disorders, general
Platelet, bleeding & clotting disorders
Musculoskeletal system disorders
Autonomic nervous system disorders
Heart rate and rhythm disorders
Reproductive disorders, female
Psychiatric disorders
Vision disorders
White cell and reticuloendothelial 
system disorders
Urinary system disorders
Endocrine disorders
Special senses other, disorders
Liver and biliary system disorders
Vascular (extracardiac) disorders
Metabolic and nutritional disorders
Red blood cell disorders
Hearing and vestibular disorders
Reproductive disorders, male
Total
1681
676
562
382
302
295
247
114
77
60
56
51
48
46
31
30
29
26
18
11
11
3
3
2
     4,761
35.3
14.2
11.8
8.0
6.3
6.2
5.2
2.4
1.6
1.3
1.2
1.1
1.0
1.0
0.7
0.6
0.6
0.5
0.4
0.2
0.2
0.1
0.1
0.0
100
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The most common ADRs in any context are usually 
hypersensitivity reactions which mainly present as 
dermatological allergic reactions and were the most 
common in this report (19). A study carried out in 
two health institutions in Pereira, Colombia, in 2005 
showed that the most common ADRs were allergic 
urticarial, hypoglycemia and acute gastritis. The 
latter two were not reported in this case, showing 
the difference between ADRs that occur in hospital 
settings and those in the outpatient setting (1).
The information obtained in this work was from 
a spontaneous report system, because the data 
are conditioned to inter-individual factors and the 
motivation of doctors and pharmaceutical chemists 
that work with the affiliated population. Passive 
pharmacovigilance has shown an important under-
reporting of the actual number of adverse events 
(5,10,22). Spontaneous reports of ADR might be 
useful for specific reactions or those with a temporal 
relationship linking them to a specific drug, but 
might be less helpful in other types of ADR such 
as cancer development (7,10).
The percentage of ADR notification, according to 
the 54 million drugs dispensed by Audifarma, S.A., 
in 2012, was 0.003%. Studies in Colombia showed 
an ADR frequency of 0.03% and 6.8% among 
hospitalized patients and 1.2% to 45% as a reason 
for consultation/hospitalization. Taking this into 
account, significant ADR underreporting occurred 
in this population (1,14).
A small percentage of ADRs were classified as 
“definitive”, which is in accordance with other 
reports and evidences the difficulty in determining 
the absolute relationship of a drug with an event 
(1,4,14). Failures in completing the on-line form 
were detected for some items that were not availa-
ble for all cases. The WHO Pharmacovigilance 
Center in Uppsala has established criteria to 
guarantee the quality of ADR reports that should 
be met by Audifarma (10).
Pharmacovigilance systems constitute a permanent 
drug monitoring tool which can reduce the morbidity, 
mortality and cost for health systems (23). The 
number of ADR reports for a drug can increase if 
there are specific warnings about it, which allows 
health institutions to focus pharmacovigilance on 
certain drugs. In the past, this behavior has allowed 
the detection of drug security problems and has 
resulted in their withdrawal from the market (4). 
We considered 5.3% as a significant percentage 
of severe ADRs, as it is above reports in Spain 
(1.1%) and below those recorded in France and 
Canada (9.6% and 24%, respectively) (24-26). The 
differences may be due to the quality of reporting 
systems (25).
Segura, et al., calculated that the cost of health 
attention due to ADR in Colombia would reach 
approximately 29.4 to 88.9 million dollars in 2010, 
hence the pertinence of preventing their occurrence 
(2). Another study from Colombia showed that the 
average cost of care for each ADR case was US$ 
78.1 (range: US$ 32 - US$ 259) (1). A study found 
that ADRs caused by anticoagulants, insulin and 
corticosteroids accounted for over 80% of global 
ADR attention cost, which shows the importance 
of certain drug groups even when they are not 
among those that are most commonly associated 
with drug reactions (19). To deepen the dilemma, 
national ADR information, collected by INVIMA, is 
not published on academic media as a tool that 
would allow improvements in decision making and 
procurement for patient security (27).
We concluded, then, that the drug groups most 
commonly related to ADRs in Colombia during 
the study period were anti-infectives for systemic 
use, cardiovascular drugs, nervous system agents, 
alimentary tract and metabolism drugs and anti-
neoplastic and immunomodulating agents, the 
latter being a novelty in our country but in line 
with their growing use. Metamizole, enalapril and 
clarithromycin were the drugs with the highest 
number of reports, which is common in the case of 
Table 5. The most commonly reported adverse drug reactions 
attributed to the first 15 drugs with the highest number of reports 
among Colombian patients, 2007-2013
Adverse reactions Frequency %
Dermatologic reaction
Phlebitis
Cough
Nausea/dizziness
Bleeding
Dyspnea
Leg edema
Headache
Emesis
Thoracic pain
Bleeding risk
Hot flush
Hypotension
Extrapyramidal symptoms
Presyncope
Epigastric pain
Tachycardia
Anxiety/excitement
Eyelid edema
Paresthesia
408
138
101
78
68
53
41
40
37
33
21
20
18
17
16
15
15
14
10
10
31.3
10.6
7.7
6.0
5.2
4.1
3.1
3.1
2.8
2.5
1.6
1.5
1.4
1.3
1.2
1.2
1.2
1.1
0.8
0.8
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the analgesic, but has led to discussion regarding 
the frequency of the uncomfortable cough asso-
ciated with the antihypertensive drug. It was also 
noteworthy that rituximab and infliximab, both 
biotechnological drugs, were among the 15 drugs 
with the highest ADR report number. Hypersensitivity 
reactions in skin, followed by phlebitis associated 
with intravenous antimicrobial use and cough, were 
the most common ADRs.
Among the limitations of this study we should 
mention that information was obtained from 
spontaneous ADR notification, and this renders a 
partial view of the events that could have happened. 
Also, the data correspond to a percentage of the 
Colombian population, so the results can only 
be extrapolated to persons with similar SGSSS 
affiliation characteristics.
The question could be asked about how much of 
the information on ADR reaches patients, a fact that 
seems to be underrated in most publications. The 
knowledge about the most common ADRs in the 
country could help patient communities to under-
stand the risk to which they are exposed by using 
certain drugs (28). As there is little ADR notification 
and reports, and national pharmacovigilance 
programs in Colombia are deficient, we think 
our results can provide knowledge on the drug 
groups most commonly associated with ADRs in 
the country, as well as information on the events 
related to the administration of biotechnological 
drugs, which is a topic that the enquiry on this kind 
of undesired results must also focus upon. Work 
needs to be done on the design of digital systems 
to immediately record adverse reactions and give 
feedback to prescribing doctors in order to prevent 
related medication errors (29). In addition, due to 
the importance of ADR notification with regard to 
public health, the possibility of paying physicians 
for each report they fill in has been suggested with 
the aim of improving the quantity and quality of 
the information received (30). Finally, we should 
consider mandatory ADR reporting and have all 
health workers report each event. People respon-
sible for health policies should create mechanisms 
to promote ADR reporting among physicians, and 
case investigation and timely notification among 
insurers and health care providers.
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